182500-01-2

Basic information

• Product Name: (E)-3-(3-hydroxy-4-nitrophenyl)acrylic acid
• Synonyms: (E)-3-(3-hydroxy-4-nitrophenyl)acrylic acid
• CAS NO: 182500-01-2
• Molecular Formula: C9H7NO5
• Molecular Weight: 209.15558
• Mol File: 182500-01-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (E)-3-(3-hydroxy-4-nitrophenyl)acrylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-3-(3-hydroxy-4-nitrophenyl)acrylic acid(182500-01-2)
• EPA Substance Registry System: (E)-3-(3-hydroxy-4-nitrophenyl)acrylic acid(182500-01-2)

Safety Data

• Hazardous Substances Data: 182500-01-2(Hazardous Substances Data)

Upstream product

• 141-82-2 malonic acid 
• 704-13-2 5-formyl-2-nitrophenol 
• 14755-02-3 3-hydroxycinnamic acid 
• 7697-37-2 nitric acid 
• 64-19-7 acetic acid 
• 14755-02-3 3-hydroxy-trans-cinnamic acid 
• 3011-34-5 4-hydroxy-3-nitrobenzaldehyde 

Downstream Products

• 1224873-10-2 (E)-N-(3-chlorophenyl)-3-(4-amino-3-hydroxyphenyl)-prop-2-enamide 
• 1224873-09-9 (E)-N-(3-chlorophenyl)-3-(3-hydroxy-4-nitrophenyl)-prop-2-enamide 

Relevant articles and documents

Nitration of cinnamic acids using cerium (IV) ammonium nitrate immobilized on silica

Treatment of cinnamic acids with cerium (IV) ammonium nitrate supported on silica (CAN/SiO2) was used to synthesize nitro derivative and ipso substitution products. The position of the substituents defines the type and the yields of the product

IL-8 RECEPTOR ANTAGONISTS

The present invention relates to novel compounds and a novel use of phenyl ureas in the treatment of disease states mediated by the chemokine Interleukin-8 (IL-8).

IL-8 RECEPTOR ANTAGONISTS

This invention relates to novel compounds and a novel use of phenyl ureas in the treatment of disease scates mediated by the chemokine, Interleukin-8 (IL-8). In particular, this invention relates to the novel compounds of Formula (Ia) and their use in treating chemokine mediated diseases wherein the chemokine binds to an IL-8 a or b receptor. Compounds of Formula (Ia) are represented by the structure: STR1 wherein interalia, X is oxygen or sulfur;Rb is NR 6 R. sub.7, alkcyl, aryl, arylC 1-4 alkyl, aryl C 2-4 alkenyl, heteroaryl, heteroarylC 1-4 alkyl, heteroarylC 2-4 alkenyl, heterocyclic or heterocyclic C 1-4 alkyl, or a heterocyclic C 2-4 alkenyl moiety, camphor, all of which may be optionally substituted; R 1 is independently selected from hydrogen; halogen; nitro; cyano; C 1-10 alkyl; halosubstituted C 1-10 alkyl; C 2-10 alkoxy; halosubstituted C 1-10 alkoxy; azide; (CR. sub.8 R 8)q S(O) t R 4 ; hydroxy; hydroxy substituted C 1-4 alkyl; aryl; aryl C 1-4 alkyl; aryl C 2-10 alkenyl; aryloxy; aryl C 1-4 alkyloxy; heteroaryl; heteroarylalkyl; heteroaryl C 2-10 alkenyl; heteroaryl C 1-4 alkyloxy; heterocyclic; heterocyclic C 1-4 alkyl; heterocyclicC 1-4 alkyloxy; heterocyclic C 2-10 alkenyl; q is 0 or an integer having a value of 1 to 10; n is an integer having a value of 1 to 3;m is an integer having a value of 1 to 3; Y is hydrogen; halogen; nitro; cyano; halosubstituted C 1-10 alkyl; C 1-10 alkyl; C 2-10 alkenyl C. sub.1-10 alkoxy; halosubstituted C 1-10 alkoxy; azide; (CR 8 R. sub.8)qS(O) t R 4, (CR 8 R 8)qOR 4 ; hydorxy; hydroxy substituted C. sub.1-4 alkyl; aryl; aryl C 1-4 alkyl; aryloxy; arylC. sub.1-4 alkyloxy; aryl C 2-10 alkenyl; heteroaryl; heteroarylalkyl; heteroaryl C 1-4 alkyloxy; heteroaryl C 2-10 alkenyl; heterocyclic, heterocyclic C 1-4 alkyl; heterocyclicC 2-10 alkenyl;or a pharmaceutically acceptable salt thereof.